Wound Management Technologies, Inc. Appoints Dr. Blaine Farless As Medical Director Of The Resorbable Orthopedic Products Subsidiary

ADDISON, TX--(Marketwired - October 14, 2014) - Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX®, today announced that the Company appointed Dr. Blaine Farless as Medical Director of the Resorbable Orthopedic Products subsidiary (ROP).

Dr. Blaine Farless, a board-certified orthopedic surgeon with 27 years of experience remarks, “Bone bleeding during surgery has always been an issue and although bee’s wax was adequate and easy to use, it prevented bone healing and created potential problems down the road. Next generation products did not cause long term problems but were difficult to use in addition to being less effective and more costly. The resorbable hemostat products in development by the ROP subsidiary of Wound Management Technologies appears to offer ease of use and cost effectiveness in addition to not slowing bone growth and avoiding long term problems. I am thrilled at the opportunity to work with the company as we bring this product to market.”

Dr. Farless is currently practicing at the Cleburne Orthopedic and Sports Medicine but is also a staff surgeon at the Texas Health Harris Methodist Hospital Cleburne and the Glen Rose Medical Center, in addition to having staffing privileges at three other hospitals throughout the Fort Worth, Texas area. He is a member of the Academy of Orthopedic Surgeons, Texas Medical Association, Texas Orthopedic Association and Texas Sports Medicine Association. Dr. Farless completed medical school at the University of Texas Health Science Center in San Antonio and holds an undergraduate degree in Chemical Engineering.

“We are excited to introduce Dr. Farless as our new Medical Director for ROP as he brings a wealth of knowledge in orthopedics in both the clinical as well as the surgical setting. Orthopedic surgery is a growth avenue for our resorbable hemostat products that are in the final stages of development. Dr. Farless is a champion of the clinical efficacy and cost-effectiveness that the product will bring to surgeries,” commented Robert Lutz, Jr., Chief Executive Officer of Wound Management Technologies.

About Wound Management Technologies
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its Wound Care Innovations subsidiary’s unique, patented collagen product line, CellerateRX® which is FDA-cleared for all wound types except 3rd degree burns. The wound care products are reimbursable under Medicare Part B and the surgical products are reimbursed as part of a procedural billing. Wound Management has other advanced biotech products in development including a patented resorbable bone hemostat line that is in late stages of development. For more information visit www.wmgtech.com.

To download Wound Management Technologies’ investor relations app, which offers access to SEC documents, press releases, audio casts and more, please visit
https://itunes.apple.com/us/app/wound-management-technologies/id913690915?ls=1&mt=8 to download on your iPhone and iPad or https://play.google.com/store/apps/details?id=com.theirapp.woundmgmt for your Android mobile device.

Information about Forward-Looking Statements
The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current
and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.